Tag : clinical trials

Neurology

ECT for Bipolar Disorder: Across-the-Board Symptom Relief

Newsemia
Electroconvulsive therapy achieved response rates of more than 80% for all symptoms of bipolar disorder and remission rates of more than 60% for several features,...
Neurology

Safety Concern With Fingolimod to Ocrelizumab Switch in MS

Newsemia
A new study has suggested that some patients who make this switch may experience "double immunosuppression" – very low levels of both T and B...
Dermatology

Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.

Newsemia
Related Articles Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol. 2020 03;32(2):106-113 Authors: Herrscher H, Robert C Abstract...
Dermatology

Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.

Newsemia
Related Articles Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting. Curr Opin Oncol. 2020 03;32(2):85-90 Authors: Tétu P, Baroudjian...
Neurology

Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed

Newsemia
The 0.5-mg dose of fingolimod provides a greater reduction in annualized relapse rate vs both the 0.25-mg dose of fingolimod and the 20-mg dose of...
Neurology

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab

Newsemia
Medscape Medical News Source link...
Neurology

Intensive Hypertension Treatment Lowers Orthostatic Hypotension

Newsemia
A new analysis provides evidence that intensive antihypertensive drug therapy does not raise the risk of orthostatic hypotension, but instead may reduce it. Medscape Medical...
Neurology

The New Neuroscience of Stuttering

Newsemia
After centuries of misunderstanding, research has finally tied the speech disorder to certain genes and brain alterations ― and new treatments may be on the...
Neurology

Novel Therapy an Alternative to ECT for Resistant Depression?

Newsemia
In a single-center study, magnetic seizure therapy produced remission from suicidal ideation in 50% of patients with treatment resistant depression. Medscape Medical News Source link...
Neurology

IMPACT-AFib: Single Mailing Fails to Budge Anticoagulant Uptake

Newsemia
A single educational mailing sent by several U.S. health plans to their patients with atrial fibrillation who were candidates for oral anticoagulation failed to boost...
Neurology

First Randomized Trial Reassures on ACEIs, ARBs in COVID-19

Newsemia
The BRACE CORONA study found no difference in key outcomes between patients continuing vs stopping their medication. Medscape Medical News Source link...
Neurology

Mini-Dose Edoxaban May Safely Cut AF Stroke Risk in Very Elderly

Newsemia
Thromboembolic risk plunged on direct oral anticoagulation at an off-label, very-low dose in octogenarians with AF who were considered too high risk for usual dosing;...
Neurology

RATE-AF Trial Boosts Digoxin for Rate Control in Permanent AF

Newsemia
Study results show equally good rate control with digoxin as with a beta-blocker, but with far fewer adverse events. Medscape Medical News Source link...
Neurology

Systolic Orthostatic Hypotension Tied to Dementia Risk

Newsemia
A new analysis may be the first to show that variability in systolic blood pressure with postural changes is associated with an increased risk for...
Cardiology

The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials.

Newsemia
Related Articles The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World